Introduction
Cardiovascular diseases are the leading cause of death in the developed countries. Other related ailments such as hereditary cardiomyopathies are also a common cause of morbidity and mortality. Gene therapy has been extensively studied as a novel strategy for heart diseases. Owing to the quiescent nature of cardiomycytes, the classic retrovirus vectors are not suitable for intracardiac gene transfer. On the other hand, adenovirus (Ad) vectors and naked plasmid DNA have been successfully used to deliver genes into the heart tissue. Ad vectors could be delivered into the myocardium either by direct intramyocardial injection 1 or through coronary circulation. 2 However, a major limitation is the vector-related immune responses in immunocompetent recipients. In addition, it is extremely difficult to deliver Ad vectors through coronary circulation, because of the large viral particle size that hinders the virus from exiting the blood vessel and infecting cardiomyocytes. Direct injection of naked DNA into myocardium could achieve gene transfer but with very limited efficiency. 3 Adeno-associated virus (AAV) vectors are based on nonpathogenic and replication-defective parvoviruses, which have small viral particle sizes (B22 nm in diameter). 4 AAV vectors have been widely used for efficient gene delivery into a variety of tissues in vivo including brain, 5 liver, 6, 7 lung, 8 muscle, 9, 10 and eye. 11, 12 Currently, AAV vectors are the most promising gene delivery system in muscle tissues due to its efficient, widespread and persistent gene transfer. Although extensive studies have been carried out using AAV vectors in skeletal muscles for both muscular dystrophies [13] [14] [15] [16] [17] [18] and for metabolic diseases, [19] [20] [21] [22] few studies involved cardiac muscles. Limb girdle muscular dystrophies are a group of heterogeneous inherited neuromuscular diseases. 23 The severe and early-onset phenotypes are usually caused by mutations in sarcoglycan (SG) genes a (LGMD 2D), b (LGMD 2E), g (LGMD2C), and d (LGMD 2F). These small transmembrane proteins associate in equal stoichiometry on muscle cell membrane to form a heterotetramer, named SG complex. 24 Recently, sarcospan was also identified as a member of the SG complex. 25 Primary deficiency of any single SG protein can result in partial or complete disappearance of the SG complex on the sarcolemma, leading to muscular dystrophy and cardiomyopathy. The cardiomyopathy Syrian hamster Bio14. 6 26 was the first available LGMD 2F animal model, with a large deletion in its d-sarcoglycan gene. 27, 28 The genetic mutation causes biochemical deficiency of the entire SG complex on both skeletal and cardiac muscle cell membranes. In addition to skeletal muscle myopathy, the Bio14.6 hamsters also suffer from severe cardiomyopathy and congestive heart failure, a primary cause of premature death. As a result of the resemblance to human patients, the Bio14.6 hamster provides an excellent animal model of gene therapy for both skeletal and cardiac deficiencies. Successful gene therapy studies on skeletal muscle in Bio14.6 hamsters have been achieved using both Ad vector 29 and AAV vectors carrying d-sarcoglycan gene, 14, 15, 18 which restored the missing sarcoglycan complex on the muscle cell membrane, improved both muscle histopathology and myofiber membrane integrity and, more importantly, recovered the muscle contractile force deficits. 15 In addition, direct local injection of an AAV vector carrying d-sarcoglycan gene into the myocardium of Bio14.6 hamster has been recently reported. 30 However, AAV vector-mediated SG gene delivery through the coronary artery into the entire myocardium has not been reported.
In this study, we have used AAV2 vectors carrying either a reporter Lac-Z gene or the d-sarcoglycan gene into the myocardium of the hamsters in a heterotopic heart transplant model. Highly efficient and persistent transgene expression and biochemical restoration of the d-sarcoglycan and the SG complex in the hamster hearts have been accomplished.
Results
Widespread and persistent transgene expression in cardiomyocytes after coronary delivery of AAV-LacZ vector Cardiomyopathy in the Bio14.6 hamster is caused by the lack of d-sarcoglycan in the cardiomyocytes. To correct the genetic deficiency, widespread and persistent expression of the therapeutic gene into a majority of the cardiomyocytes is desirable. Direct intramyocardium injection of the vectors apparently could not render widespread gene transfer throughout the heart. To investigate whether highly efficient gene transfer can be achieved by the coronary circulation, we initially tested an AAV-Lac-Z reporter vector in a heterotopic heart transplantation model. 31 The reason to choose the ex vivo heart transplant method instead of the in situ heart gene transfer is mainly because of the technical difficulty of the latter method in small rodents.
To test and compare the transduction efficiency of AAV2 and Ad5 vectors in hamster hearts, healthy F1B hamster donor hearts were infused ex vivo through coronary circulation with 200 ml of AAV-CMV-Lac-Z or Ad-CMV-LacZ virus (1 Â 10 12 viral genomes, v.g.), and then transplanted into the abdomen of recipients of the same strain. A 2 weeks after vector delivery, X-gal staining of the AAV vector-treated heart showed robust and widespread LacZ gene expression in a vast majority of the cardiomyocytes (Figure 1a) , while the Ad vectortreated heart showed inefficient gene transfer with few LacZ-positive cardiomyocytes (Figure 1b) . Cross-sectioning of the whole heart 1 year after AAV gene transfer revealed LacZ-positive myocytes in up to 90% of the heart tissue ( Figure 1c) . A preference of gene transfer by the AAV2 vectors in peripheral areas over the central areas of the myocardium was occasionally observed (data not shown; Figure 3 ). This might be due to the differences in blood vessel densities in those muscles. No signs of immune cell infiltration and immune rejection of AAV-LacZ-transduced myocytes were observed. These results demonstrated that the AAV vector could be effectively delivered into the myocardium through , and stained by X-gal and H&E on the cryo-thinsections of the transplanted hearts 2 weeks after vector infusion (photographs were taken with a Â 20 lens). AAV-CMV-LacZ also conferred long-term, intracardiac gene expression for 1 year (c), while the control heart without gene transfer showed no X-gal staining (d) (photographs of the whole-heart crosssection were taken with a Â 4 lens and spliced together). The dystrophic Bio14.6 hamster hearts were infused with AAV-CMV-dSG vector and immunofluorescently stained with anti-d-SG antibody and Cy3-labeled secondary antibody (e) at 4 months after vector infusion (photograph of the wholeheart cross-section was taken with a Â 2 lens). The untreated Bio14.6 heart showed no fluorescent staining (f) (photograph was taken with a Â 20 lens).
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Efficient AAV-d-sarcoglycan gene transfer in cardiomyocytes and restoration of sarcoglycan complex
Having succeeded in normal hamster heart with a reporter gene, we next investigated whether the therapeutic gene d-sarcoglycan could also be efficiently transduced into the hearts of the diseased Bio14.6 hamsters by AAV2. In a similar manner, hearts isolated from Bio14.6 hamster donors were infused ex vivo via coronary circulation with 200 ml of AAV-d-sarcoglycan (1 Â 10 12 viral genomes, v.g.) and then transplanted into the abdomen of Bio14.6 hamster recipients. As the average lifespan of the Bio14.6 hamsters was reportedly 5 months, 26 the AAV vector-treated and heterotopically transplanted hearts were examined for transgene expression at 4 months after gene transfer (5 months of age). Immunofluorescent staining was performed on the crosssections of the vector-transduced hearts with a monoclonal antibody specific to human d-sarcoglycan, which was the AAV transgene product in this study. The results showed extensive gene expression in a majority of the cardiomyocytes in the entire heart (Figure 1e ). Similar to our previous studies in the skeletal muscles, 14, 15 AAV-dsarcoglycan gene transfer resulted in overexpression of the protein in some of the myocytes, and revealed cytoplasmic staining as well as membrane staining of the protein (Figure 2d and d 0 ). However, overexpression of the d-sarcoglycan did not interfere with the restoration of the other three SG components (a-, b-, and g-sarcoglycans) onto the plasma membrane of the cardiomyocytes (Figure 2a-c) . No cytoplasmic staining of a-, b-, and g-sarcoglycans in AAV vector-transduced myocytes was observed, which is again consistent with the results obtained in skeletal muscle gene transfer. 14, 15 Thus, expression of d-sarcoglycan in the Bio14.6 hamster hearts effectively restored the missing SG complex.
Protection of cardiomyofiber plasma membrane integrity
The restoration of the SG complex should also render a protective effect on the cardiomyocyte cell membrane integrity and prevent membrane leakage. To examine the protective effect, Evans blue dye (a low molecular weight dye with red fluorescence) was injected into the Bio14.6 hamsters treated with AAV-d-sarcoglycan. Examination of the cardiac muscle showed exclusion of Evans blue dye in the sarcoglycan-positive heart tissue ( Figure 3 , left half, b-sarcoglycan staining on the cell membrane) and leakage into the myocytes in the areas without AAV gene transfer ( Figure 3 , right half, red fluorescence of Evans blue dye in the cytoplasm of leaking cardiomyocytes), indicating a protective effect on plasma membrane integrity by the SG gene therapy.
Inefficient transgene expression in blood vessels
Since the AAV vectors were delivered into the myocardium through coronary circulation and robust transgene expression was observed in cardiomyocytes, we wished to examine whether the blood vessels were also transduced. Cross-sections of hearts transduced by the AAV-LacZ vector were analyzed for transgene expression in the blood vessels, which were surrounded by highly transduced cardiomyocytes to assure that those blood vessels also had been exposed to the AAV vectors. Intracardiac gene transfer by AAV vectors J Li et al Surprisingly, no X-gal staining could be observed in blood vessels of various sizes in the AAV-LacZ-treated hamster hearts, although their neighboring myocytes were all highly transduced and showed strong X-gal staining (Figure 4a and b) . These results suggested that AAV-2 vectors were inefficient in delivering transgene expression in cardiac blood vessels.
Discussion
Previously, efficient gene transfer and therapeutic benefits have been demonstrated in the skeletal muscles of the dystrophic Bio14.6 hamsters after gene therapy with the AAV-d-sarcoglycan vectors. 14, 15, 18 In this study, we showed that coronary infusion of AAV vectors into the hearts is an efficient method of gene transfer into the myocardium. Widespread and sustained transgene expression in the hearts of both healthy and dystrophic hamsters was accomplished. AAV-d-sarcoglycan gene transfer also restored the entire missing SG complex, whose deficiency is the primary cause of the cardiomyopathy and congestive heart failure in the Bio14.6 hamsters as well as in some sarcoglycanopathy patients.
Intracardiac gene transfer has been one of the major emphases in the field of gene therapy. Both Ad vectors and naked plasmid DNA vectors have been extensively studied for intracardiac gene transfer. These vectors have also been used in clinical trials of cardiovascular diseases to deliver therapeutic genes that promote local angiogenesis in the ischemic heart tissues. 1, 3 For that purpose, limited local gene transfer may be sufficient to render therapeutic effects. However, for hereditary cardiomyopathies and other heart conditions where extensive gene transfer is required, adenoviral and nonviral vectors would face formidable hurdles to achieve widespread transgene expression. When delivered through blood circulation, both Ad vectors and naked plasmid DNA were not only hindered by their size constraint in exiting the capillary blood vessels, but also limited by the extracellular matrix barrier 32, 33 and the lack of receptors for naked DNA on the cardiomyocytes. Recently, Ad vectors carrying Lac-Z reporter gene and d-sarcoglycan gene were delivered into the heart of normal and Bio14.6 hamster hearts after transient aortic occlusion.
2 To achieve efficient intracardiac gene transfer, both hypothermia and cardioplegia were also required. In addition, the use of histamine in the coronary circulation for several minutes before Ad delivery was essential to achieve sufficient blood vessel fenestration and leakage to allow the Ad to enter the extravascular space. 2 By contrast, AAV vectors have much smaller particle sizes (B22 nm in diameter) than the Ad (B100 nm in diameter including fibers). As a result, AAV vectors can bypass the blood vessel pores and extracellular matrix with less difficulty. In fact the vectors have been investigated for intracardiac gene transfer by means of both coronary circulation and direct intramyocardium injection. An early study in pig hearts with an AAV-LacZ vector delivered by a catheter into a branch of the coronary artery achieved transgene expression in large numbers but only a small overall percentage of cardio- Figure 3 Protection of myocyte membrane integrity by AAV-CMV-dSG gene transfer. The hamster was injected intravenously with Evans blue dye to examine the myocyte plasma membrane integrity. Cryo-thin-section of vector-treated heart was immunofluorescently stained with anti-b-SG antibody, showing the restoration of the SG complex on the cell membrane (left portion of the photograph, taken with a Â 4 lens) and prevention of dye leakage into those cells. By contrast, the areas without gene transfer and negative for b-SG staining (right portion of the photograph) had numerous myocytes leaked and filled with Evans blue dye (it has strong red fluorescence) in the entire cytoplasm, as highlighted by arrows. Note: As d-SG showed some cytoplasm accumulation (see Figure 2) , the anti-b-SG antibody was instead used to assure that the red cytoplasm fluorescence was a result of Evans blue dye leakage.
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J Li et al mycytes, 34 probably due to insufficient vector doses. Direct intramyocardium injection of AAV vectors also rendered efficient local gene transfer in hamster heart and therapeutic benefits in the TO-2 hamster, 30 a derivative of the cardiomyopathy Bio14.6 hamsters. In our study, AAV vectors were directly infused through the aorta into the coronary artery without extra pressure and without the use of histamine or blood vessel dilating chemicals. Highly efficient and widespread gene transfer in the whole heart indicated that AAV viral particles were small enough to exit the capillary blood vessels and infect the cardiomyocytes. Under the same ex vivo condition, an adenovirus LacZ vector, however, failed to achieve significant gene transfer (Figure 1b) . The use of histamine and papaperin was necessary for efficient gene transfer in the same ex vivo heart transplant model when an Ad vector was used. 18 Given the smaller particle sizes, AAV vectors should face less difficulties than the Ad vectors. [34] [35] [36] Owing to the technical difficulty for in situ gene delivery into the hearts of small rodents via coronary circulation, we employed the heterotopic heart transplant, a widely used model in the transplant field, to examine AAV-mediated gene transfer in the cardiomyopathic Bio14.6 hearts. Although widespread d-sarcoglycan gene transfer and restoration of the entire SG complex were accomplished in the vector-treated hearts, it is difficult to evaluate the physiological functions of such a heart because the transplanted heart did not have normal blood circulation in the left ventricle. This makes echocardiograph and hemodynamics evaluations nonapplicable. An improved transplant model should offer a solution to this problem. 37 In addition, the lack of mechanical stress to the heart may also minimize the contraction-induced damage to the dystrophic heart muscle, resulting in less severe phenotypes. Nonetheless, we still observed the Evans blue dye leakage into the myocytes in the areas that lacked d-sarcoglycan gene transfer, and the protection of myocytes membrane integrity in the area that showed d-sarcoglycan gene transfer ( Figure 3) . As a result the high percentage of therapeutic gene transfer in the cardiomyocytes, a recovery in physiological functions would almost be certain if the heart were in its in situ position. This notion is supported by two previous studies, where either a direct injection of left ventricle muscle with an AAV-d-sarcoglycan vector 30 or a coronary infusion with an Ad-d-sarcoglycan vector 2 have achieved significant physiological function recovery. The AAV vector treatment also slightly prolonged the lifespan of the cardiomyopathic TO-2 hamsters even though only a portion of the left ventricle received gene transfer by a single local injection of the d-sarcoglycan vector. To achieve clinical relevance, in situ perfusion of the diseased heart has to be performed, which is technically difficult but feasible.
Finally, it is also interesting to note the lack of detectable transgene expression in the blood vessels of the AAV vector-treated heart, both with the LacZ reporter gene or with the d-sarcoglycan gene (data not shown), despite the extensive transgene expression in the surrounding myocytes. This phenomenon may be a result of inefficient infection of blood vessel cells by AAV2-based vectors, which could be possibly limited by the lack of receptor 38 and coreceptors, 39, 40 impaired intracellular trafficking, and inability of viral DNA second-strand DNA synthesis. Alternatively, it may also be the result of promoter shutoff in those cells. Given the implication of blood vessel deficiency in some sarcoglycanopathy-related heart failure, 41 it would be interesting to see whether extensive gene correction in the cardiomyocytes, rather than the cardiovasculature, would render a complete or a partial therapeutic efficacy. A combination of gene therapy and drug therapy 42 may be required to achieve maximal benefits. 
Materials and methods

Production of AAV vectors
Construction of AAV vectors containing human dsarcoglycan cDNA or b-galactosidase (Lac-Z) gene under the control of CMV promoter (AAV-CMV-dSG) has been previously described (Li) . The recombinant viral vector stocks were produced by cotransfection methods as described by Xiao et al. 43 The AAV viral vectors were purified twice through CsCl density gradient purification according to the previously published protocols. 9, 44 The vector titers of viral genome particle number were determined by DNA dot blot method, 44 and were in the range of 5 Â 10 12 viral genome (v.g.) particles per ml. An adenovirus CMV-LacZ vector was made by the standard protocol 9 and the vector titer was 5 Â 10 12 viral genome particles per ml.
Coronary artery delivery of AAV and Ad vectors
Healthy F1B and dystrophic Bio14.6 hamsters were purchased from Bio Breeders (Fitchburg, MA, USA) and handled in accordance with the institutional guidelines of the University of Pittsburgh. Heterotopic heart transplantation was done on 1-2-month-old animals. The method for heterotopic heart transplantation was adapted from the rat procedure of Ono and Lindsey. 31 All animals were anesthetized with tribromoethanol (Avertin s , 250 mg/kg i.p.). The heart was transplanted into the abdomen with end-to-side anastomosis of aorta to aorta and pulmonary artery to vena cava. For ex vivo intravascular vector injection into the donor heart after harvest, cold AAV2-CMV-LacZ vector or AAV2-CMVdSG (0.2 ml in DMEM media) or Ad5-CMV-LacZ (0.2 ml in PBS saline) was quickly infused into the aorta, which was clamped so that the vector solution would flow through the coronary circulation and irrigate the entire myocardium. No recirculation of the vector solution was performed. The heart was soaked in cold saline for 5-10 min and then transplanted into the abdominal cavity of the syngeneic recipients. The heart graft contraction was monitored weekly by palpation. AAV-CMV-LacZ gene expression was detected by X-gal staining, while AAV-CMV-dSG gene expression was detected by immunofluorescent staining of the cryostat thin sections of the vector-treated hearts. To test the cardiomyocyte cell membrane integrity in vivo, Evans blue dye (10 mg/ml PBS) was injected intravenously into Bio14.6 hamsters at 0.1 mg/g of body weight. The animals were killed 12 h after dye injection. Vector-treated hearts were collected and cryosectioned. Evans blue dye positive cardiomyocytes, which showed red fluorescence in the cytoplasm, were observed under the fluorescent microscope with Rhodamine filters.
Immunofluorescent staining
Cryostat sectioning of the heart tissue was performed at 5 mM thickness with a Leica microtome. For immunofluorescent staining, 15 the unfixed muscle cryosections were immediately blocked in 10% horse serum and PBS at room temperature for 1 h. Monoclonal antibodies against a-, b-, g-, and d-sarcoglycan SGs (Novocatra Laboratories) were diluted 1:100 in 10% horse serum/ PBS, and incubated with the cryosections for 2 h at room temperature. After three washes, the sections were incubated with Cy-3-labeled anti-mouse antibody at 1:500 dilution in 10% horse serum/PBS (Jackson Immuno Research Laboratories). After three washes, the samples were mounted in Gelmount (Fisher). Photographs were taken with a Nikon fluorescent microscope equipped with a digital camera.
